Selzentry (maraviroc)

News alerts, weekly reports and conference planners

Company:

ViiV Healthcare

Drug class:

CCR5 receptor antagonist

Related drugs:

‹

›

MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	pembrolizumab + maraviroc Sensitive: C3 – Early Trials pembrolizumab + maraviroc Sensitive : C3	pembrolizumab + maraviroc Sensitive: C3 – Early Trials pembrolizumab + maraviroc Sensitive : C3
CCL5 overexpression	Glioblastoma	CCL5 overexpression	Glioblastoma	maraviroc Sensitive: D – Preclinical maraviroc Sensitive : D	maraviroc Sensitive: D – Preclinical maraviroc Sensitive : D

Associations
(2)